Ronnie F. Luyun

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

Thomas E. Witzig, Susan M. Geyer, Irene M. Ghobrial et al. · Journal of Clinical Oncology · 2005 · 520 citations

Medicine, Oncology, Pharmacology +17

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)

Aminah Jatoi, Howard L. Ritter, Amylou C. Dueck et al. · Lung Cancer · 2009 · 218 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

Thanyanan Reungwetwattana, Julian R. Molina, Sumithra J. Mandrekar et al. · Journal of Thoracic Oncology · 2012 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study

Alex A. Adjei, Julian R. Molina, Shauna L. Hillman et al. · Journal of Clinical Oncology · 2007 · 37 citations

Medicine, Oncology, Pharmacology +14

Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group

Stephen M. Ansell, Susan M. Geyer, Paul J. Kurtin et al. · Journal of Clinical Oncology · 2006 · 19 citations

Medicine, Oncology, Pharmacology +17